Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

US Department of Justice
Express Scripts

Generated: June 25, 2017

DrugPatentWatch Database Preview

Claims for Patent: 4,357,324

« Back to Dashboard

Claims for Patent: 4,357,324

Title: Prodrug derivatives of 9.beta.-D-arabinofuranosyl-2-fluoroadenine
Abstract:The 5'-formate and the 5'-phosphate derivatives of 9-.beta.-D-arabinofuranosyl-2-fluoroadenine have been prepared as prodrug forms of the anti-cancer agent 9-.beta.-D-arabinofuranosyl-2-fluoroadenine, known as F-ara-A. These derivatives are quite water soluble whereas F-ara-A itself is sparingly soluble in water or in any organic solvents. Delivery of these prodrug forms to mice with L1210 leukemia results in the formation of higher levels of the triphosphate of F-ara-A, the active form of the drug, in the target L1210 leukemia cells. These prodrug forms are much more active chemotherapeutically than 9-.beta.-D-arabinofuranosyladenine, known as ara-A, and equivalent in activity to the combination of ara-A and 2'-deoxycoformycin, known as 2'-dCF, an effective in vivo inhibitor of adenosine deaminase, a ubiquitous enzyme that destroys ara-A in vivo.
Inventor(s): Montgomery; John A. (Birmingham, AL), Shortnacy; Anita T. (Birmingham, AL)
Assignee: The United States of America as represented by the Department of health (Washington, DC)
Application Number:06/237,617
Patent Claims: 1. 9-(5-O-formyl-.beta.-D-arabinofuranosyl)-2-fluoroadenine.

2. A method for treating L1210 cancer in mice by administration of an aqueous solution of an effective amount of an agent consisting of 5'-O-formyl derivative of O-.beta.-D-arabinofuranosyl-2-fluoroadenine.

3. A method of treating mouse cancer according to claim 2 wherein an oral dosage is administered in an effective amount of a dosage of 10 to 250 mg/kg/day in a unitary regimen.

4. 9-(5-O-phosphate-.beta.-D-arabinofuranosyl)-2-fluoroadenine.

5. A method of treating L1210 mouse cancer by administration of an aqueous solution of an effective amount of an agent consisting of 5-O-phosphate derivative of O-.beta.-D-arabinofuranosyl-2-fluoroadenine.

6. A method of treating mouse cancer by administration of an effective amount of an aqueous solution of 5' phosphate of 9-.beta.-D-arabinofuranosyl-2-fluoroadenine.

7. A method for treating L1210 cancer in mice wherein the 5' phosphate of 9-.beta.-D-arabinofuranosyl-2-fluoroadenine is administered in an effective amount of a dosage of 10 to 250 mg.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Federal Trade Commission
Queensland Health
Harvard Business School
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:

Google Plus